PI states risk of GI Perforations (GIP) incr w/ IL-6i (1.1--2.6/1000PYs) & JAKi (~1-2/1000PY) . French Insurance pop. study of ~40K pts on JAKi or adalimumab found NO no signif difference betw JAK v ADA (IR: 2.1 vs 1.1/1000PYs; p=0.65). https://t.co/YlxiBOhNFj https://t.co/A5hMbWDXeV
Links:
Risk of gastrointestinal perforation in patients with rheumatic diseases expose…
https://buff.ly/3JZn3HA
May-13-2024
